[A20-40] Neratinib (breast cancer) - Addendum to Commission A19-98

Last updated 14.05.2020

Project no.:
A20-40

Commission:
Commission awarded on 06.04.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer if prior adjuvant trastuzumab-based therapy was completed less than one year ago

Result of dossier assessment:

Due to new information from the commenting procedure now hint of a non-minor added benefit.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2020-05-14 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form